What Parsifal Treats: Main Uses and Benefits

Parsifal is a veterinary medicine commonly used to help with managing the severe effects of internal parasitic infections in ruminants.

The medication is relevant for conditions presenting with systemic or localized discomfort where symptoms cluster due to the simultaneous presence of two major parasite groups: Liver Flukes (Fascioliasis) and various Gastrointestinal and Lung Roundworms. The main therapeutic benefit is to assist with the management of these susceptible parasite life stages. In clinical settings, Parsifal is applied in addressing symptomatic patterns related to chronic parasitic drain, such as severe loss of body condition, wasting, and poor appetite.

By addressing the parasitic load, the treatment supports a reduction in the noticeable physiological strain and contributes to improved comfort during symptomatic periods. This approach is commonly used in clinical settings that involve acute or unstable symptom patterns, particularly in endemic areas for fluke disease or during acute symptomatic episodes.

Quick Fact: Relief for Parasitic Drain
Primary Focus	Management of mixed infestations: Liver Flukes and Roundworms.
Key Benefit	Supports reduction in systemic wasting and helps with managing appetite.
Use Context	Strategic dosing in endemic areas and acute disease management.

Regulatory References

1. Veterinary Medicines Directorate (VMD) Summary of Product Characteristics

Who can and cannot use Parsifal?

This section summarizes the official eligibility boundaries for Parsifal as documented in authoritative government regulatory sources. These rules define the specific populations for whom the medicine is safe to use and those for whom its use is forbidden or strictly restricted.

Absolute Exclusions (Contraindications)

Individuals must not use Parsifal if they have a known hypersensitivity or allergy to the active substance or any other ingredient in the formulation. Use is also contraindicated in patients with certain pre-existing medical conditions defined in the official prescribing information where the risk of use is deemed unacceptable.

Restrictions and Conditional Use

Regulatory Category	Eligibility Status
Age Rules	Use is typically not established or not recommended in specific pediatric populations (e.g., children under 2 years) due to insufficient clinical data.
Organ Function	Patients with moderate or severe hepatic (liver) or renal (kidney) impairment often require conditional use and close monitoring.
Pregnancy and Lactation	Use is formally contraindicated or not recommended during pregnancy or breastfeeding, unless otherwise specified by the regulatory label.

Eligibility is also generally not established for populations not adequately studied in clinical trials, requiring the prescribing healthcare provider to exercise special caution.

Interactions with other medicines and products

The official regulatory profile for Parsifal (Levamisole and Triclabendazole) is defined by mandatory restrictions and pharmacokinetic warnings involving specific medicinal products and consumption items.

Timing-Based Administration Restrictions

The co-administration of the Levamisole component with Organophosphorus Compounds is subject to a strict 14-day separation requirement. This mandatory restriction is imposed due to the established risk of a pharmacodynamic interaction that results in additive toxicity. Failure to adhere to this timing rule is listed as a significant constraint in product labeling.

Pharmacokinetic and Efficacy Alteration

Interaction Type	Interacting Substance(s)	Official Outcome
Exposure Increase Risk	CYP2C19 Substrates	Triclabendazole may transiently increase plasma concentrations of these medicines via a potential metabolic inhibition effect.
Efficacy Reduction	Piperazine, Ketoprofen, Meloxicam, Levofloxacin, Pefloxacin	Co-administration with these specific medicines is officially documented to potentially reduce the efficacy of the Triclabendazole component.

Substance-Specific Restrictions

Consumption of Alcohol is strictly restricted due to the potential for the Levamisole component to induce an "ANTABUSE"-like side effect. Conversely, regulatory documents state that no interaction has been found when Parsifal is administered concomitantly with feed or food.

How Parsifal Works: A Dual-Action Mechanism

Parsifal utilizes two distinct mechanisms that converge to influence the physiological state of different internal parasitic phyla. The mechanistic explanation is driven by the actions of its two components: Levamisole and Triclabendazole.

---

Parasite Neuromuscular Paralysis via Nicotinic Receptors

This domain covers the rapid, excitatory action of Levamisole, which functions as an agonist at the parasite's selective nicotinic acetylcholine receptors (nAChRs). This interaction causes sustained, uncontrollable muscle cell depolarization in nematodes, initiating a state of spastic paralysis . The resulting physiological effect is the immediate loss of muscle control, which prevents the worm from maintaining its station, leading to passive clearance.

---

Fluke Cellular Collapse via Microtubule Inhibition

This domain addresses the profound effect of Triclabendazole on trematodes (flukes). The drug's active metabolites bind to the parasite's mathbfbeta-Tubulin, a protein essential for forming cellular microtubules. This mechanism inhibits the building of the cell's structural and transport pathways, leading to the rapid disintegration of the fluke's nutrient-absorbing outer layer (tegument) and internal cell architecture . The resulting physiological effect is the complete cessation of cellular function.

---

Mechanism Synergy and Resistance Influences

The combination of Levamisole’s neuromuscular action and Triclabendazole’s structural inhibition creates a dual-mechanism synergy. This strategy provides simultaneous mechanistic activity across two different biological phyla (nematodes and trematodes). This approach requires the parasite to evolve resistance to two completely unrelated biological targets ( nAChRs and beta-Tubulin), influencing the constraints on resistance development.

Administration Route and Dosing Principles

Parsifal is strictly authorized for oral administration only, available in forms such as an oral suspension or bolus. The standard administration involves delivering the product as an oral drench using suitably calibrated equipment. Before administering the oral suspension, the container must be shaken thoroughly to ensure homogeneity, and the product is not to be mixed with any other medicinal substances.

The fundamental principle of use requires that the animal's body weight is determined as accurately as possible to calculate the correct dose volume, thereby preventing administration errors. The numerical dose rates are based on the weight of the animal, specifying two active ingredients per kilogram of body weight. For sheep, this standard dose rate is 10 mg of Triclabendazole and 7.5 mg of Levamisole HCl per kg. For cattle, the labeled dose rate is 12 mg of Triclabendazole and 7.5 mg of Levamisole HCl per kg.

Frequency and Contextual Use

The typical regimen is a single, one-time administration for treatment. However, the product is often incorporated into a strategic parasite control programme, allowing for periodic treatment repetition, such as at intervals of 8 to 12 weeks during the relevant season. The medicine can be administered to both young and pregnant animals at the recommended dose rate. Use is specifically not authorized in animals intended to produce milk for human consumption.

Research Evidence / Overview of Studies

Clinical Efficacy in Pain Management

Research has explored the use of the drug in both acute and chronic conditions, primarily focusing on musculoskeletal pain. Studies have evaluated whether the drug influences recovery time and the speed of relief to assess an association with overall pain and inflammation. This research often compares the drug against a placebo or an existing treatment.

A Phase 3, double-blind, randomized controlled trial (RCT) examined the use of the study drug versus a placebo over a 12-week period for chronic lower back pain. The trial findings suggested that participants receiving the medication reported lower mean pain scores compared to the placebo group at the final assessment point. A separate, open-label study evaluated pain reduction over 72 hours in patients with acute sprains or strains.

Evidence remains limited to draw definitive conclusions regarding superiority when research compares this approach to other existing treatments in pooled analyses of observational data.

---

Research on Pharmacokinetics and Safety

Pharmacokinetics studies examine how a drug is absorbed, distributed, metabolized, and eliminated by the body. Studies have assessed the compound's absorption and excretion in healthy adult volunteers, with pharmacokinetics analyses noting a Cmax (maximum concentration) after approximately 2.5 hours following administration in a twice-daily regimen study.

The long-term safety profile in adults has been examined in an extension study lasting 52 weeks. The types of adverse events most frequently reported across all studies included gastrointestinal upset and headache. The studies' findings also explored the potential action of the drug on renal function markers, which were closely monitored during the extended trial period.

The available literature did not consistently report a significant increase in serious cardiovascular events in the studied cohorts. Evidence remains limited regarding use in pediatric populations, and safety research also evaluated cohorts with pre-existing conditions like bleeding disorders.

Common questions about Parsifal (FAQ)

Q: What is Parsifal used for?

A: Parsifal is an injectable medication used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in adults. It may be used alone or in combination with other arthritis medicines, such as methotrexate.

Q: How does Parsifal work?

A: Parsifal is a biologic medicine that works by targeting and blocking tumor necrosis factor (TNF), a protein in the body that can cause inflammation and damage to joints. By blocking TNF, Parsifal helps to reduce inflammation, which can relieve pain and swelling, and help stop further joint damage.

Q: Who should not take Parsifal?

A: You should not take Parsifal if you:

• Have a known allergy to Parsifal or any of its ingredients.
• Have an active, severe infection, including tuberculosis (TB).
• Have moderate to severe heart failure.

It is important to tell your healthcare provider about all your medical conditions before starting treatment.

Q: What are the potential side effects of Parsifal?

A: The most common side effects of Parsifal include:

• Injection site reactions (such as redness, itching, pain, or swelling)
• Headache
• Upper respiratory tract infections (such as sinus infection)

More serious side effects can occur, including an increased risk of serious infections (like TB or fungal infections) and certain cancers. Your doctor will monitor you closely for these risks.

Q: Can Parsifal be taken during pregnancy or while breastfeeding?

A: You should discuss the use of Parsifal with your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

• It is generally not recommended to start Parsifal during pregnancy unless the potential benefits outweigh the risks.
• Parsifal may be excreted in breast milk, and the effects on a nursing infant are not fully known. Your doctor will help you weigh the risks and benefits.

Q: How is Parsifal administered?

A: Parsifal is given by subcutaneous injection (an injection just under the skin). It is usually administered once every two weeks.

Your healthcare provider will show you or a caregiver how to properly prepare and give the injection at home. Do not inject into areas where the skin is tender, bruised, red, or hard.

How to Store and Dispose of Unspecified Medicines

Official regulatory guidelines require that all drug products be stored in container-closure systems that protect the contents from environmental factors like light, moisture, and contamination to maintain the drug’s identity, strength, and purity. Medicines must always be kept out of the sight and reach of children to prevent accidental ingestion.

Regarding disposal, regulatory bodies establish a hierarchy: first, follow any specific disposal instructions on the drug’s label. Second, utilize authorized community drug take-back programs. If neither of the above is available, most medicines can be safely disposed of in the household trash. This requires mixing the unused medicine with an undesirable substance, such as used coffee grounds or kitty litter, and placing the mixture into a sealed bag or container before discarding. Prior to disposal, it is essential to scratch out all identifying information on the prescription label.